Craig Venter’s Synthetic Genomics Inc. (SGI) announced that it is joining hands with Integrated DNA Technologies (IDT) the leading supplier of oligonucleotides to manufacture, market, and commercialize synthetic gene products. In a press release, Synthetic Genomics said that SGI and IDT wil construct synthetic, double-stranded nucleic acids of size up to 5 kb.
SGI was founded in 2005 by Craig Venter and Nobel Laureate Hamilton O. Smith. The genome sequencing pioneer, Craig Venter, after completing the private funded human genome sequencing effort competing with the public funded human genome, focused on research on synthetic cells and engineering genomics. In 2010 Craig Venter’s J. Craig Venter Institute (JCVI) successfuly constructed first self-replicating synthetic bacterial cell through SGI sponsored funding. And now SGI is putting the technologies developed to commercial use.
Making the announcement, J. Craig Venter, Ph.D., the genomics veteran and the founder CEO of SGI said that
We believe that our agreement with IDT is a key component to advance our synthetic DNA business,” said. “We look forward to working with the market leader IDT in developing important products for the life sciences community.
IDT’s founder and added Dr. Joe Walder, Founder and Chief Executive Officer, IDT.
We are pleased to be partnering with Synthetic Genomics. Through this collaboration we plan to apply SGI’s cutting edge technologies to create more affordable, efficient gene synthesis products that can be delivered more quickly to the synthetic biology community.